View Clinical Trial (Medical Research Study)

Is Topiramate Effective in Treating Dizziness in Patient's With Migraine-Associated Dizziness - NCT00732108-94143(Clinical Trial 235474)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  San Francisco
State:  
CA
Zip Code: 94143
Conditions: Migraine - Headache - Dizziness
Purpose: The purpose of this study is to determine whether topiramate effective in treating dizziness symptoms that are associated with migraine headaches.
Study summary: Migraine is a common disorder, often associated with dizziness symptoms. In many cases, dizziness is one of the only manifestations of migraine headaches. Various classes of drugs have been advocated as treatment for migraine-associated dizziness, though none has been shown to be superior over the others. Topiramate is a drug approved for migraine prophylaxis. This study is designed to assess if there are significant changes in dizziness frequency and severity in patients diagnosed with migraine-associated dizziness treated with topiramate. Demonstrating benefit of topiramate with a placebo-controlled study to alleviate symptoms of dizziness would serve to clarify effective treatment options for patients with migraine-associated dizziness.
Criteria: Inclusion Criteria: - Clinical diagnosis of migraine-associated dizziness. Exclusion Criteria: - Previous or current use of topiramate prior to study enrollment. - Need for continued use of the following medications for any medical reason during the study: ergots, anti-epileptics, beta-blockers, calcium channel blockers, monoamine oxidase inhibitors, high-dose magnesium, high-dose riboflavin, corticosteroids, local anesthetics, botulinum toxin, or herbal preparations. - History of nephrolithiasis. - Women whom are pregnant or breastfeeding. - Patients with known sensitivity to topiramate. - Patients with a history of glaucoma. - Patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study.
Study is available at: University of California, San Francisco
San Francisco, CA 94143
United States

Primary Contact:
Laura O'Neill
Email: ONeillL@neurology.ucsf.edu
Phone: 415-885-7861

Secondary Contact:
Lawrence R Lustig, M.D.
Email: dizzy@headache.ucsf.edu
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.